1.
Reumatismo
; 75(4)2023 Dec 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38115771
RESUMO
Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria set out in the prescription forms.